A detailed history of Wolverine Trading, LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Wolverine Trading, LLC holds 4,999 shares of MDGL stock, worth $1.54 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,999
Previous 4,582 9.1%
Holding current value
$1.54 Million
Previous $1.28 Million 17.38%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$212.22 - $292.96 $88,495 - $122,164
417 Added 9.1%
4,999 $1.06 Million
Q2 2024

Aug 14, 2024

BUY
$193.33 - $291.99 $885,838 - $1.34 Million
4,582 New
4,582 $1.28 Million
Q4 2023

Feb 14, 2024

BUY
$120.4 - $237.13 $34,434 - $67,819
286 Added 6.78%
4,503 $1.04 Million
Q3 2023

Nov 15, 2023

SELL
$146.04 - $225.78 $812,858 - $1.26 Million
-5,566 Reduced 56.89%
4,217 $615,000
Q2 2023

Aug 23, 2023

BUY
$203.88 - $312.0 $895,644 - $1.37 Million
4,393 Added 81.5%
9,783 $2.26 Million
Q1 2023

May 15, 2023

BUY
$231.06 - $307.08 $1.25 Million - $1.66 Million
5,390 New
5,390 $1.27 Million
Q2 2022

Aug 15, 2022

BUY
$58.04 - $100.2 $236,280 - $407,914
4,071 Added 163.23%
6,565 $472,000
Q1 2022

May 16, 2022

SELL
$55.89 - $101.89 $484,789 - $883,793
-8,674 Reduced 77.67%
2,494 $248,000
Q4 2021

Feb 14, 2022

BUY
$72.34 - $95.09 $496,831 - $653,078
6,868 Added 159.72%
11,168 $948,000
Q3 2021

Nov 12, 2021

BUY
$78.35 - $105.02 $145,731 - $195,337
1,860 Added 76.23%
4,300 $344,000
Q2 2021

Aug 06, 2021

BUY
$97.2 - $137.59 $26,146 - $37,011
269 Added 12.39%
2,440 $237,000
Q1 2021

May 14, 2021

BUY
$108.54 - $125.2 $10,419 - $12,019
96 Added 4.63%
2,171 $253,000
Q2 2020

Aug 13, 2020

BUY
$60.13 - $125.71 $124,769 - $260,848
2,075 New
2,075 $213,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.28B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Wolverine Trading, LLC Portfolio

Follow Wolverine Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.